• Citer

Long-term results of the randomized phase III trial EORTC 18991 of adjuvant therapy with pegylated interferon alfa-2b versus observation in resected stage III melanoma.

par Eggermont, A;Suciu, Stefan ;Testori, Alessandro;Santinami, M.;Kruit, Wim H;Marsden, Jeremy;Punt, Cornelis;Sales, François ;Dummer, Reinhard;Robert, Caroline;Schadendorf, Dirk;Patel, Poulam;de Schaetzen, Gaetan;Spatz, Alain;Keilholz, Ulrich
Référence Journal of clinical oncology, 30, 31, page (3810-3818)
Publication Publié, 2012-11

Article révisé par les pairs

• Détails
• Contenu

Résumé :

Adjuvant pegylated interferon alfa-2b (PEG-IFN-α-2b) was approved for treatment of resected stage III melanoma in 2011. Here, we present long-term follow-up results of this pivotal trial.